Company profile
Marizyme, Inc.
OTC: MRZM · Healthcare · Biotechnology
#910 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 43GM —SS 38
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), 3-yr revenue growth · ↓ net margin, filing timeliness
Methodology →Revenue TTM
$183.4k
Rev growth YoY (TTM)
-69.0%
Net income (FY)
-$65.3M
Employees
13
as of 2026-08-28
Market cap
$39.5k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$645.8k$645.8k2023
Net income-$65.3M-$65.3M2023
Operating income-$34.1M-$34.1M2023
Total assets$22.0M$22.0M2023
Liabilities$26.7M$26.7M2023
Equity-$4.7M-$4.7M2023
Revenue trend
FY2017 – FY2023 · USD
FY17
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2022
By product
Royalty100%
By geography
Not disclosed.
The read
What is Marizyme, Inc.’s revenue?
Marizyme, Inc. booked $645.8k in FY2023 revenue, growing 177% year over year — faster than most Healthcare companies we track, at a -10118.6% net margin.
Peers · Healthcare
SETO Holdings, Inc.54DLexeo Therapeutics, Inc. Common Stock37DPolomar Health Services, Inc.28DBioXcel Therapeutics, Inc.27DComera Life Sciences Holdings, Inc.——CEN Biotech, Inc.——Neighbors
Palm Beach →Key facts
CEODavid L. Barthel
SectorHealthcare
IndustryBiotechnology
HeadquartersJupiter, FL
ExchangeOTC: MRZM
Employees13
IPO date2010-11-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.